Therapy News and Research

RSS

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical Inc. is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis.

24 Nov 2009

Studies demonstrate clinical utility of Given Imaging's PillCam SB capsule endoscopy

Given Imaging Ltd., the global leader in patient-friendly GI diagnostic and monitoring solutions, today announced three new studies that demonstrate the clinical utility of PillCam SB capsule endoscopy in providing physicians with critical information on how they manage and/or diagnose intestinal disorders. These novel studies were carried out in pediatric patients with gastrointestinal symptoms, including children with known or suspected Crohn's disease.

24 Nov 2009

Shire submits a MAA for velaglucerase alfa in Europe

Shire plc, the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company's enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease.

24 Nov 2009

Second-quarter fiscal 2010 results announced by Medtronic

Medtronic, Inc. today announced financial results for its second quarter of fiscal year 2010, which ended Oct. 30, 2009.

24 Nov 2009

Positive data from Æterna Zentaris' Phase 2 targeted cytotoxic peptide conjugate study

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.

24 Nov 2009

Americans with hepatitis C are at increased risk of developing liver cancer, says NVHR

New peer-reviewed data finding that fewer than one-fifth of the nearly 4 million Americans infected with chronic hepatitis C virus have received anti-viral therapy in recent years should be a wake-up call that Congress needs to move urgently on bipartisan legislation to support new state-based detection, research, and surveillance efforts, the National Viral Hepatitis Roundtable (NVHR) said today.

24 Nov 2009

About Face Acne Foundation to provide best-in-class therapy for indigent acne patients

Acne is a serious medical condition. More than 40 percent of mid-teens and adolescents have either acne or acne scarring requiring professional treatment by a dermatologist. Unfortunately, nationwide statistics show that only 11 percent of patients receive treatment.

24 Nov 2009

StemCells commences patient recruitment for a Phase I clinical trial of HuCNS-SC in PMD

StemCells, Inc. announced today that it has commenced patient recruitment for a Phase I clinical trial designed to test the safety and preliminary efficacy of its HuCNS-SC® purified human neural stem cells in Pelizaeus-Merzbacher Disease (PMD), a neurological disorder that primarily afflicts children. The study is being conducted at the University of California, San Francisco (UCSF) Children’s Hospital, one of the leading medical centers in the United States for neonatology, pediatric neurology and neurosurgery.

24 Nov 2009

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

Two recent FDA approvals have prompted the National Comprehensive Cancer Network (NCCN) to update the NCCN Clinical Practice Guidelines in Oncology(TM) for Non-Hodgkin's Lymphomas to include ofatumumab (Azerra(TM), GlaxoSmithKline) and romidepsin (Istodax(R), Gloucester Pharmaceuticals) as treatment options for select patients with two types of Non-Hodgkin's Lymphomas.

24 Nov 2009

DSS sets evidence-based guidelines and definitions to treat type 2 diabetes

A first-of-its-kind consensus statement on diabetes surgery is published online today in the Annals of Surgery. The report illustrates the findings of the first international consensus conference -- Diabetes Surgery Summit (DSS) -- where an international group of more than 50 scientific and medical experts agreed on a set of evidence-based guidelines and definitions that are meant to guide the use and study of gastrointestinal surgery to treat type 2 diabetes. The document is considered to be the foundation of diabetes surgery as a medical discipline of its own.

24 Nov 2009

Medical center leaders celebrate BRTI's 25th anniversary

Considered a highly risky and controversial medical procedure only 25 years ago, solid organ transplantation is now a life-saving mainstream operation thanks to the extraordinary men and women who gathered at the Winspear Opera House in Dallas on Nov. 11.

24 Nov 2009

2009-10 AACP Student Community Engaged Service Award announced

Four student-led community engagement projects will be awarded the 2009-10 AACP Student Community Engaged Service Award for their outstanding programs delivering consumer education about medication use, expanding access to affordable healthcare and improving the public’s health.

24 Nov 2009

BioAlliance Pharma's AMEP biotherapy reduces both tumour growth and tumour angiogenesis

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented preclinical results on its new biotherapy, AMEP™ for advanced and metastatic melanoma at the ESGCT (European Society of Gene and Cell Therapy) in Hannover (November 21 to 25, 2009).

24 Nov 2009

Team-based care and medical homes may improve chronic disease management

Patients whose hypertension is managed by a physician-pharmacist team have lower blood pressure levels and are more likely to reach goals for blood pressure control than those treated without this collaborative approach, according to a report in the November 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

24 Nov 2009

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma ASA, the clinical stage oncology focused pharmaceutical company, and Clovis Oncology, Inc., the newly formed oncology company led by former Pharmion Corporation executives, announced today an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.

24 Nov 2009

Treatment rates for hepatitis C virus declining, say researchers

Researchers from the University of Michigan determined that only 663,000 of the approximately 3.9 million Americans with hepatitis C virus (HCV) infection received antiviral therapy between 2002 and 2007.

24 Nov 2009

Antiviral therapy for hepatitis C appears to be declining in the U.S.; lack of diagnosis is primary barrier to treatment

23 Nov 2009

New initiative launched to take care of patients with sickle cell disease

The Medical College of Georgia is leading an initiative that could result in a paradigm shift in the care of patients with sickle cell disease.

23 Nov 2009

Inadequate asthma control is present in 26% to 45% of children, says review

Asthma is the commonest chronic disease in children and a major reason for admissions to hospital, yet inadequate asthma control is present in 26% to 45% of children, states a review http://www.cmaj.ca/embargo/cmaj071638.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

23 Nov 2009

Guardian examines challenge of testing, treating patients with HIV/AIDS in Kenya

The Guardian examines the challenge of testing and treating some of the estimated 1.4 million people living with HIV/AIDS in Kenya. "Deep-rooted stigma and patchy health education has led many to cower from the disease, which has seen the country's life expectancy rates shortened by 20 years in the last two decades," the newspaper writes. Even though "[t]he country's government has supplied antiretroviral therapy (ART) to suppress the virus to patients for free since 2006, … of the 390,000 adults estimated as being eligible for ART at the time of the survey, around 140,000, or 35%, were taking the medication," according to a 2007 country survey.

23 Nov 2009

Therapy News and Research

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Studies demonstrate clinical utility of Given Imaging's PillCam SB capsule endoscopy

Shire submits a MAA for velaglucerase alfa in Europe

Second-quarter fiscal 2010 results announced by Medtronic

Positive data from Æterna Zentaris' Phase 2 targeted cytotoxic peptide conjugate study

Americans with hepatitis C are at increased risk of developing liver cancer, says NVHR

About Face Acne Foundation to provide best-in-class therapy for indigent acne patients

StemCells commences patient recruitment for a Phase I clinical trial of HuCNS-SC in PMD

NCCN Guidelines adds ofatumumab and romidepsin as therapy options for CLL

DSS sets evidence-based guidelines and definitions to treat type 2 diabetes

Medical center leaders celebrate BRTI's 25th anniversary

2009-10 AACP Student Community Engaged Service Award announced

BioAlliance Pharma's AMEP biotherapy reduces both tumour growth and tumour angiogenesis

Team-based care and medical homes may improve chronic disease management

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Treatment rates for hepatitis C virus declining, say researchers

Antiviral therapy for hepatitis C appears to be declining in the U.S.; lack of diagnosis is primary barrier to treatment

New initiative launched to take care of patients with sickle cell disease

Inadequate asthma control is present in 26% to 45% of children, says review

Guardian examines challenge of testing, treating patients with HIV/AIDS in Kenya

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News